IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ent Application of runo Criere et al.

Filing Date:

Application No.: 10/030,262

April 17, 2002

Group Art Unit: 1615

Examiner: LAKSHMI SARADA CHANNAVAJJA

Confirmation No.: 8894

Title: PHARMACEUTICAL COMPOSITION CONTAINING FENOFIBRATE AND THE PREPARATION

METHOD

FIFTH INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:			
	nclosed is a 449 for the above		Information Disclosure Statement and accompanying form nt application.
	The fee of \$18 A statement ur A statement ur § 1.17(p) are a Charge A check in the	0.00 (1806) as der 37 C.F.R. der 37 C.F.R. lso enclosed to Depo	on of an IDS is required. s set forth in 37 C.F.R. § 1.17(p) is also enclosed. § 1.97(e) is also enclosed. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.F. osit Account No. 02-4800 for the fee due. is enclosed for the fee due.
1.21 th	he Director is here	eby authorized d by this paper	edit card. Form PTO-2038 is attached. to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and and to credit any overpayment, to Deposit Account No. 02-4800
			Respectfully submitted,
			BUCHANAN INGERSOLL PC
Alexar	Box 1404 ndria, Virginia 223 336-6620	13-1404	By Brian P. O'Shaughnessy
Date:	October 21, 2005		Registration No. 32,747



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Patent Application of

Bruno Criere et al.

Application No.: 10/030,262

Filed: April 17, 2002

For:

PHARMACEUTICAL COMPOSITION CONTAINING FENOFIBRATE AND

THE PREPARATION METHOD

Group Art Unit: 1615

Examiner: LAKSHMI SARADA

CHANNAVAJJALA

Confirmation No.: 8894

FIFTH INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

A fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

10/24/2005 HALI11

00000078 10030262

01 FC:1806

180.00 OF

BUCHANAN INGERSOLL PC (including attorneys from burns doane swecker & mathis)

Date October 21, 2005

P.O. Box 1404

Alexandria, Virginia 22313-1404

(703) 836-6620

Brian R. O'Shaughnessy

Registration No. 32,747

Substitute for form 1449A/PTO & 1449B/PTO **FIFTH** INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/030,262 April 17, 2002 **Filing Date** Bruno Criere et al. **First Named Inventor** LAKSHMI SARADA **Examiner Name** 017751-030 **Attorney Docket Number**

OCT 2 1 2005

(use as many sheets as necessary)

Sheet of

Issue/Publication Date (MM-DD-YYYY) **U.S. PATENT DOCUMENTS** Document Examiner Kind Code Name of Patentee or Applicant Initials Number of Cited Document (if known) 4,752,470 Mehta 4,717,569 Harrison et al. 01-05-1988 5,145,684 Liversidge et al. 09-08-1992 4,412,986 Kawata et al. 11-01-1983 3,914,286 Mieville 10-21-1975 4,058,552 Mieville 11-15-1977 07-07-1998 5,776,495 Duclos et al.

FOREIGN PATENT DOCUMENTS											
		STATUS									
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	EP 793 958	A2	EP	09-10-1997	X						
	WO 98/31360		PCT	07-23-1988							
	WO 82/01649		PCT	05-27-1982							
	EP 0164 959		EP	12-18-1985							
	WO 96/01621		PCT	01-25-1996							
	EP 012523		EP	06-25-1980							
	<u> </u>										
		ļ									\Box
						<u> </u>					

	NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	A. Munoz et al., "Micronised Fenofibrate", <i>Atherosclerosis</i> 110 (Suppl.) (1994) S45-S48, Elsevier Science, Ireland					
	D.F. Temeljotov et al., "Solubilization and Dissolution Enhancement for Sparingly Soluble Fenofibrate", Acta. Pharm. 46 (1996) 131-136					
	I. Ghebre-Sellassie "Pellets: A General Overview", <i>Pharmaceutical Pelletization Technology, Drugs and the Pharmaceutical Sciences</i> , 37 , pp. 2, 3, 234, edited by Isaac Ghebre-Sellassie, Marcel Dekker, Inc. NY NY					
	R. Bianchini et al., "Influence of Drug Loading on Coated Beads Release Using Air Suspension Technique", Boll. Chim. Farmaceutico, 128 Dec. 12, 1989, pp. 373-379					
	Dr. Bernhard Luy, "Methods of Pellet Production", Presented at Glatt Symposium, Strasbourg, Oct. 1992, pp 1-12, with curriculum vitae					
	A. Kuchiki et al., "Stable Solid Dispersion System Against Humidity", Yakuzaigaku 44(1) 31-37 (1984) pp. 1-13					
	JP Guichard et al., "A New Formulation of Fenofibrate: Suprabioavailable Tablets", Current Medical Research and Opinion 16 (2) (2000) pp. 134-138, Laboratoires Fournier, France					

Signature Considered	Examiner		Date		 -
	Signature		Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.